Legend Biotech (LEGN) Return on Capital Employed (2020 - 2025)
Legend Biotech (LEGN) reported Return on Capital Employed of 51.73% for Q4 2025, up 2665.0% on a YoY basis from 1.87% in Q4 2024, and up 30.48% quarter-over-quarter from 39.64% in Q3 2025.
Legend Biotech (LEGN) Return on Capital Employed (2020 - 2025) Analysis & Trends
Legend Biotech has reported Return on Capital Employed for 6 years, with the latest figure at 51.73% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed rose 2665.0% year-over-year to 51.73%; the trailing twelve-month figure through Dec 2025 stood at 51.73% (up 2665.0% YoY), and the FY2025 full-year result was 12.81%, up 808.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 51.73%, up from 39.64% in the prior quarter.
- The five-year high for Return on Capital Employed was 5372.09% in Q2 2024, with the low at 1781.34% in Q4 2021.
- Historically, Return on Capital Employed has averaged 1135.6% across 5 years, with a median of 39.64% in 2025.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 533217 bps — and 2025, when it slumped 533780 bps.
- Legend Biotech's Return on Capital Employed stood at 1781.34% in 2021, then surged by 103 bps to 45.59% in 2022, then jumped by 10676 bps to 4913.13% in 2023, then plunged by 99 bps to 25.08% in 2024, then surged by 106 bps to 51.73% in 2025.
- The last three Return on Capital Employed figures came in at 51.73% (Q4 2025), 39.64% (Q3 2025), and 34.29% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 10.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.73% |
| Sep 30, 2025 | 39.64% |
| Jun 30, 2025 | 34.29% |
| Mar 31, 2025 | 31.40% |
| Dec 31, 2024 | 25.08% |
| Sep 30, 2024 | 5,340.57% |
| Jun 30, 2024 | 5,372.09% |
| Mar 31, 2024 | 5,123.67% |
| Dec 31, 2023 | 4,913.13% |
| Sep 30, 2023 | 35.62% |
| Jun 30, 2023 | 39.93% |
| Mar 31, 2023 | 42.87% |
| Mar 31, 2022 | 45.59% |
| Dec 31, 2021 | -1,781.34% |
| Sep 30, 2021 | -3.00% |
| Jun 30, 2021 | -1.76% |
| Mar 31, 2021 | -4.28% |
| Dec 31, 2020 | 0.08% |
| Sep 30, 2020 | 0.04% |